Adaptive Biotechnologies

Contributing Author

Recent Articles by Adaptive Biotechnologies

Sep-01	Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference ADPT GlobeNewswire
Jul-29	Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results ADPT ADPT +7.18% GlobeNewswire
Jul-09	Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026 ADPT +8.13% GlobeNewswire
Jun-17	Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering ADPT GlobeNewswire
Jun-15	Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses ADPT GlobeNewswire
Jun-15	Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering ADPT GlobeNewswire
May-29	At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ MRD Testing Across Hematology Clinical Practice and Research ADPT GlobeNewswire
May-21	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences ADPT GlobeNewswire
May-05	Adaptive Biotechnologies Reports First Quarter 2026 Financial Results ADPT GlobeNewswire
Apr-15	Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026 ADPT GlobeNewswire
Feb-05	Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results ADPT GlobeNewswire
Jan-27	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences ADPT GlobeNewswire
Jan-22	Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 ADPT +8.48% GlobeNewswire
Jan-12	Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results ADPT +15.86% GlobeNewswire
Dec-30	Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference ADPT GlobeNewswire
Dec-15	Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer ADPT GlobeNewswire
Dec-09	Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease ADPT ADPT +5.92% GlobeNewswire
Dec-06	Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting ADPT GlobeNewswire
Nov-24	Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting ADPT +9.94% GlobeNewswire
Nov-06	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences ADPT -11.54% GlobeNewswire
Nov-05	Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results ADPT GlobeNewswire
Oct-15	Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025 ADPT +9.82% GlobeNewswire
Aug-27	Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference ADPT GlobeNewswire
Aug-05	Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results ADPT ADPT +5.79% GlobeNewswire
Jul-15	Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025 ADPT GlobeNewswire
Jul-01	Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ MRD Testing into OncoEMR ADPT GlobeNewswire
May-30	Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers ADPT GlobeNewswire
May-28	Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference ADPT GlobeNewswire
May-01	Adaptive Biotechnologies Reports First Quarter 2025 Financial Results ADPT ADPT +33.70% GlobeNewswire

Adaptive Biotechnologies

Recent Articles by Adaptive Biotechnologies

Upgrade your Finviz experience